Menu
← Oncology Approval Tracker
FDA DECISION ·
Sarclisa Escena + carfilzomib + dexamethasone
subcutaneous isatuximab-irfc with carfilzomib and dexamethasone · Sanofi
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory multiple myeloma after one to three prior lines of therapy.
LAMPGEN ANALYSIS
Why it matters
This makes subcutaneous isatuximab available in a second relapsed-disease combination. IZALCO supplied regimen-specific response data from a phase 2 study.
What research teams should watch
Match prior-line counts and the specific combination to the order set. Formulation training still needs to account for the accompanying drugs and their safety procedures.
PRIMARY RECORDS